Y. Hayashi et al., P-selectin monoclonal antibody may attenuate the whole body inflammatory response induced by cardiopulmonary bypass, ASAIO J, 46(3), 2000, pp. 334-337
Cardiopulmonary bypass (CPB) is known to induce an inflammatory response in
association with neutrophil mediated lung injury. P-Selectin has been repo
rted to be involved in the initiation of this inflammatory response by prom
oting the adhesion of neutrophils to endothelial cells in postcapillary ven
ules. However, the role of P-selectin in the inflammatory response induced
by CPB has never been clarified. To elucidate its role, we evaluated the ef
fect of an anti-rat specific P-selectin monoclonal antibody (ARP2-4; Sumito
mo Pharmaceutical) on the response of inflammatory cytokines and lung injur
y in a rat-CPB model. Twenty Sprague-Dawley rats underwent CPB for 30 minut
es (80 ml/kg per minute, 34 degrees C) under one of two conditions. In grou
p P, ARP2-4 (3 mg/kg) was added to the priming solution of the bypass circu
it (n = 10). Saline alone was given to group C (0 = 10). Inflammatory cytok
ines (tumor necrosis factor-alpha [TNF-alpha], interleukin[IL]-1 beta , IL-
6, and IL-8) and respiratory index (RI) as a marker of pulmonary gas-exchan
ge ability were measured 1) before the initiation of CPB, 2) at the termina
tion of CPB, and 3) 2 hours after the termination of CPB. Neither TNF-alpha
nor IL-1 beta was detected during the experimental period in either group.
The plasma levels of IL-6 and IL-8 increased after CPB in both groups, but
they were significantly lower in group P than in group C. The RI value inc
reased in a pattern similar to that of the inflammatory cytokines and was s
ignificantly lower in group P. These data demonstrate that the addition of
an anti-rat specific monoclonal antibody inhibits the abnormal release of i
nflammatory cytokines and attenuates CPB induced lung injury in rats. Thus,
P-selectin may play a role in the augmentation of CPB induced inflammatory
response, and the use of its inhibitory monoclonal antibody seems to be a
promising strategy for the treatment of CPB induced lung injury.